RABILITE-LS CAPSULE

Capsules

RABILITE-LS CAPSULE

PACKING:
60x10x1x10 Capsules

COMPOSITION:
Each hard gelatin capsule contains:
Rabeprazole Sodium
I.P.
20 mg
(As enteric coated pellets)
Levosulpiride
75 mg
(As sustained release pellets)
Excipients
q.s.
 
DESCRIPTION:
Rabeprazole is called a proton pump inhibitor or an 'acid pump inhibitor' and Levosulpiride is substituted benzamide antipsychotics.
 
MECHANISM OF ACTION:
Rabeprazole sodium belongs to the class of anti-secretory compounds, the substituted benzimidazoles, which do not exhibit anticholinergic or H2 histamine antagonist properties, but suppress gastric acid secretion by the specific inhibition of the H+/K+-ATPase enzyme (the acid or proton pump). The effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus. Rabeprazole is converted to the active sulphenamide form through protonation and it subsequently reacts with the available cysteines on the proton pump. Levosulpiride is the levo-rotatory enantiomer of sulpiride, a benzamide derivative selectively inhibiting dopaminergic D 2 receptors both in the trigger zone in the central nervous system and in the gastrointestinal tract.
 
INDICATIONS:
Used for hyperacidity, dyspepsia, gastro-oesophageal reflux disease.
 
CONTRAINDICATIONS:
Contraindicated in patients with rise in prolactin level and hypersensitivity. Levosulpiride is contraindicated in the Children less than 14 years of age, History of epilepsy. The drug is known to be secreted in breast milk, so, its use should be restricted in breastfeeding women.
 
SIDE EFFECTS:
Headache, skin rash, itching, diarrhoea, abdominal pain, constipation.
 
DOSAGE:
As directed by the physician.
 
STORAGE:
Store protected from light and moisture at a temperature not exceeding 25oC.
 
PRESENTATION:
10 x 10 capsules in a unit carton
 
0108906044108714, 0118906044108711, 0128906044108718